The Prostate Cancer Therapeutics Market 2014-2024
Opportunities for Leading Companies

世界の前立腺がん治療市場予測:前立腺がん治療薬、前立腺がん治療デバイス

◆タイトル:The Prostate Cancer Therapeutics Market 2014-2024
Opportunities for Leading Companies
◆商品コード:VISG409047
◆調査・発行会社:visiongain
◆発行日:2014年7月
◆ページ数:208
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single user licence(1名使用)GBP1,799 ⇒換算¥278,845見積依頼/購入/質問フォーム
Dept Licence(部署内共有可)GBP2,999 ⇒換算¥464,845見積依頼/購入/質問フォーム
Site Licence(同一国内社内共有可)GBP4,999 ⇒換算¥774,845見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界の前立腺がん治療市場予測:前立腺がん治療薬、前立腺がん治療デバイス"について調査・分析し、レポートサマリー、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、市場環境分析、研究開発パイプライン分析、専門家の見解、主要企業分析、結論などの情報をお届けいたします。

Where is the prostate cancer therapeutics market heading? Visiongain’s brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 208-page report provides 160 tables, charts, and graphs. Our new study lets you assess leading drugs and devices in the prostate cancer therapeutics market, showing their prospects to 2024. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of four exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Professor Malcolm Mason, Cancer Research UK
- Hans Kolam, Chief Financial Officer and Helen Tuvesson, Chief Scientific Officer, Active Biotech
- Dr. Estuardo Aguilar-Cordova, Co-Founder, CEO and Chairman, Advantagene

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you see revenue forecasts to 2024 for the main submarkets:
• Prostate cancer drugs
• Prostate cancer devices

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for prostate cancer drugs and devices
How will leading drugs perform to 2024 at the world level? Our study forecasts sales of 9 leading prostate cancer drugs, including these:
• Zytiga sales forecast 2014-2024
• Lupron sales forecast 2014-2024
• Xtandi sales forecast 2014-2024
• Zoladex sales forecast 2014-2024
• Casodex sales forecast 2014-2024
• Jevtana sales forecast 2014-2024
• Provenge sales forecast 2014-2024
• Taxotere sales forecast 2014-2024
• Xofigo sales forecast 2014-2024

Our new study also discusses promising drugs in the late stages of development.
How will the prostate cancer devices market perform to 2024? Our study forecasts sales for the main device submarkets, including these:
• The brachytherapy market forecast 2014-2024
• The radical prostatectomy market forecast 2014-2024
• The external beam radiation market forecast 2014-2024
• The cryotherapy market forecast 2014-2024
• The HIFU market forecast 2014-2024

Discover how high revenues can go. You see what’s happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world market into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 13 national markets to 2024:
• US
• Japan
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• Brazil
• Russia
• India
• China
• South Korea
• Mexico
• Rest of the World

There will be growth in established pharmaceutical and medical devices markets and in developing countries. Our analyses show that India, Brazil, China and Mexico, in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and pricing will influence the market.

Leading companies and potential for market growth
Overall world revenue for prostate cancer therapeutics will reach $7bn in 2014, our work forecasts. We predict steady revenue growth from 2014 to 2024. Rising demand for prostate cancer drugs and procedures, expanding healthcare coverage and the success of novel diagnostics will increase sales to 2024.

Our work shows you what organisations hold greatest potential. See profiles of 7 leading companies, including these:
• Johnson and Johnson
• AstraZeneca
• Sanofi
• AbbVie
• Varian Medical Systems
• Elekta
• Theragenics Corporation (Juniper)

A company profile gives you the following information:
• Discussion of a company’s activities and outlook
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures.

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

【レポートの目次】

1. Report Overview
1.1 The Prostate Cancer Therapeutics Market Overview
1.2 Prostate Cancer Therapeutics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. Introduction to Prostate Cancer
2.1 What is Cancer?
2.2 Phenotypic Characteristics of Cancer Cells
2.2.1 Uncontrollable Growth
2.2.2 Loss of Apoptosis Pathways
2.2.3 Lack Differentiation
2.2.4 Increased Angiogenesis
2.2.5 Potential for Metastasis
2.2.6 Genetic Instability
2.3 What Causes Cancer?
2.4 Worldwide Prevalence of Cancer: A Global Picture
2.5 What is Prostate Cancer?
2.6 Worldwide Prevalence of Prostate Cancer: Rapid Global Growth
2.7 Risk Factors for Prostate Cancer
2.8 How is Prostate Cancer Diagnosed?
2.8.1 PSA Testing
2.8.2 Digital Rectal Examination Testing
2.8.3 Prostate Cancer Screening: Beneficial or Costly?
2.8.4 Newly Approved Tests May Improve Diagnosis
2.8.4.1 Prostate Cancer Diagnostics in the Pipeline
2.9 Treatment Sequence for Prostate Cancer
2.9.1 Localised Prostate Cancer: Surgery/Radiation is Most Preferred
2.9.1.1 Brachytherapy
2.9.1.2 Radical Prostatectomy
2.9.1.3 External Beam Radiation Therapy
2.9.1.4 Cryotherapy
2.9.1.5 High-Intensity Focussed Ultrasound (HIFU)
2.9.2 Advanced Local or Metastatic Prostate Cancer: Androgen Deprivation Therapy
2.9.3 Non-Metastatic CRPC: Ketoconazole and Anti-Androgens
2.9.4 Metastatic CRPC: Expanding the Standard Taxotere Treatment Paradigm
2.9.5 First Line Chemotherapy: Docetaxel is a Standard Treatment
2.9.6 Post Docetaxel Therapy: Five FDA Approved Drugs
2.9.7 Second Line Chemotherapy: Jevtana Approved in 2010

3. The Prostate Cancer Therapeutics Market 2014-2024
3.1 The Global Prostate Cancer Therapeutics Market, 2013
3.2 The Global Prostate Cancer Therapeutics Market Forecast, 2014-2024
3.3 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints, 2014-2024

4. The Prostate Cancer Drugs Market 2014-2024
4.1 The Prostate Cancer Drugs Market: Increasing Choice of Drugs will Mean Higher Competition
4.2 The Prostate Cancer Drugs Market, 2013
4.3 Leading Prostate Cancer Drugs: Market Forecast, 2014-2024
4.3.1 The Market Shares of Leading Prostate Cancer Drugs, 2014-2024
4.4 First Generation Chemotherapies
4.4.1 Taxotere (Sanofi)
4.4.1.1 Taxotere Sales, 2013
4.4.1.2 Taxotere Sales Forecast, 2014-2024
4.5 Second Generation Chemotherapies
4.5.1 Jevtana (Sanofi)
4.5.1.1 Jevtana Sales, 2013
4.5.1.2 Jevtana Sales Forecast, 2014-2024
4.6 First Generation Hormones
4.6.1 Casodex (AstraZeneca)
4.6.1.1 Casodex Sales, 2013
4.6.1.2 Casodex Sales Forecast, 2014-2024
4.6.2 Lupron (AbbVie)
4.6.2.1 Lupron Sales, 2013
4.6.2.2 Lupron Sales Forecast, 2014-2024
4.6.3 Zoladex (AstraZeneca)
4.6.3.1 Zoladex Sales, 2013
4.6.3.2 Zoladex Sales Forecast, 2014-2024
4.7 Second Generation Hormones
4.7.1 Zytiga (Johnson & Johnson)
4.7.1.1 Zytiga Sales, 2013
4.7.1.2 Zytiga Sales Forecast, 2014-2024
4.7.2 Xtandi (Medivation/ Astellas Pharma)
4.7.2.1 Xtandi Sales, 2013
4.7.2.2 Xtandi Sales Forecast, 2014-2024
4.8 Immunotherapies
4.8.1 Provenge (Dendreon Corporation)
4.8.1.1 Provenge Sales, 2013
4.8.1.2 Provenge Sales Forecasts, 2014-2024
4.9 Radiopharmaceuticals
4.9.1 Xofigo (Bayer)
4.9.1.1 Xofigo Sales, 2013
4.9.1.2 Xofigo Sales Forecast, 2014-2024
4.10 Other Drugs
4.11 Prostate Cancer Drugs Pipeline, 2014
4.11.1 Phase III Development
4.11.1.1 DCVax-Prostate (NorthWest Biotherapeutics)
4.11.1.2 Tookad Soluble (Steba Biotech)
4.11.1.3 ProstAtak (Advantagene)
4.11.1.4 Tasquinimod (Active biotech AB/Ipsen)
4.11.1.5 Custirsen (Oncogenex/ Teva)
4.11.1.6 Cabozantinib (Exelixis)
4.11.1.7 Prostvac (Bavarian Nordic)
4.11.2 Failed Phase III Drugs
4.11.2.1 Custirsen (OncoGenex)
4.11.2.2 Yervoy (Bristol Myers Squibb)
4.11.2.3 Orteronel (Millenium Pharmaceuticals)
4.11.3 Phase II development
4.11.3.1 GDC-0980 (Roche)
4.11.3.2 GDC-0068 (Roche)
4.11.3.3 PSMA ADC (Progenics Pharmaceuticals)
4.11.3.4 Galeterone (Tokai Pharmaceuticals)
4.11.3.5 OGX-427 (OncoGenex Pharmaceuticals)
4.11.3.6 ARN-509 (Johnson & Johnson)
4.11.3.7 Abituzumab (Dl7E6) (Merck)
4.11.3.8 Ipilimumab (Yervoy) (Bristol Myers Squibb)
4.11.4 Phase I
4.11.4.1 ASG-5ME (Agensys/Seattle Genetics)
4.11.4.2 EMD-525797 (EMD Serono)
4.11.4.3 MGAH22 (MacroGenics)
4.11.4.4 RG7450 (Roche)
4.11.4.5 BAY2010112 (Bayer Pharmaceuticals)
4.11.4.6 BX-201 (Bellicum Pharmaceuticals)
4.12 The Leading Companies in the Prostate Cancer Drugs Market, 2014
4.12.1 Johnson & Johnson (J&J)
4.12.1.1 Sales and Performance Analysis, 2013
4.12.1.2 Pharmaceutical Segment Sales Analysis, 2013
4.12.1.3 Oncology Drugs Sales and Performance Analysis, 2013
4.12.1.4 Pharmaceutical Segment R&D Performance Analysis, 2013
4.12.1.5 Recent M&A Activity
4.12.1.5.1 Acquisition of Aragon Pharmaceuticals
4.12.2 AstraZeneca
4.12.2.1 Sales and Performance Analysis, 2013
4.12.2.2 Pharmaceutical Segment Sales Analysis by Segment, 2013
4.12.2.3 Oncology Drugs Sales and Performance Analysis, 2013
4.12.2.4 R&D Performance Analysis, 2013
4.12.3 Sanofi
4.12.3.1 Sales and Performance Analysis, 2013
4.12.3.2 Sales and Performance Analysis by Segment, 2012
4.12.3.3 Oncology Sales and Performance Analysis, 2013
4.12.3.4 R&D Performance Analysis, 2013
4.12.3.5 Oncology Pipeline Portfolio
4.12.4 AbbVie
4.12.4.1 Sales and Performance Analysis, 2013
4.12.4.2 R&D Performance Analysis, 2013
4.12.4.3 Oncology Portfolio Pipeline Products, 2013

5. The Prostate Cancer Devices Market 2014-2024
5.1 The Prostate Cancer Devices Market 2013
5.2 The Prostate Cancer Devices Market Forecast, 2014-2024
5.2.1 The Market Shares of Leading Prostate Cancer Devices Submarkets, 2014-2024
5.3 The Brachytherapy Market, 2014-2024
5.4 The Radical Prostatectomy Market 2014-2024
5.4.1 Intuitive Surgical’s da Vinci Surgical System will Drive Market Growth
5.5 The External Beam Radiation Therapy Market, 2014-2024
5.6 The HIFU Market, 2014-2024
5.7 The Cryotherapy Market, 2014-2024
5.8 Leading Companies in the Prostate Cancer Devices Market 2014-2024
5.8.1 Varian Medical Systems
5.8.1.1 Sales and Performance Analysis, 2013
5.8.1.2 Oncology Segment Sales Analysis, 2013
5.8.1.3 Sales Analysis by Region, 2013
5.8.1.4 R&D Performance Analysis, 2013
5.8.1.5 Key Oncology Products, 2013
5.8.1.6 Varian and Siemens Partnership: Shaping the Future of Cancer Care
5.8.2 Elekta
5.8.2.1 Sales and Performance Analysis, 2013
5.8.2.2 Sales and Performance Analysis by Region, 2012
5.8.2.3 Elekta and Philips Establish Research Consortium
5.8.2.4 Product Launch and Development, 2013
5.8.3 Theragenics Corporation (acquired by Juniper)
5.8.3.1 Theragenics Sales Performance Analysis, 2012
5.8.3.2 Theragenics Sales Performance by Operation, 2012
5.8.3.3 Theragenics sales and Performance Analysis by Business Unit, 2012
5.8.3.4 Mergers and Acquisitions
5.8.3.4.1 Juniper’s acquisition of Theragenics
5.8.3.4.2 Acquisition of Needle Tech Products
5.8.3.4.3 Acquisition of Galt Medical
5.8.3.4.4 Acquisition of CP Medical

6. The Leading National Markets 2014-2024
6.1 Regional Breakdown of the Prostate Cancer Therapeutics Market, 2013
6.2 The Prostate Cancer Therapeutics Market: Regional Forecast, 2014-2024
6.2.1 Market Shares Forecasts of Leading National Prostate Cancer Therapeutics
Markets, 2014-2024
6.3 The US Prostate Cancer Therapeutics Market 2014-2024: Largest National Market
6.4 The European Prostate Cancer Therapeutics Market, 2013
6.4.1 The European Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.1 The German Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.2 The French Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.3 The UK Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.4 The Spanish Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.5 The Italian Prostate Cancer Therapeutics Market, 2014-2024
6.5 The Japanese Prostate Cancer Therapeutics Market, 2014-2024
6.6 The Brazilian Prostate Cancer Therapeutics Market, 2014-2024
6.7 The Russian Prostate Cancer Therapeutics Market, 2014-2024
6.8 The Indian Prostate Cancer Therapeutics Market, 2014-2024
6.9 The Chinese Prostate Cancer Therapeutics Market, 2014-2024
6.10 The South Korean Prostate Cancer Therapeutics Market, 2014-2024
6.11 The Mexican Prostate Cancer Therapeutics Market, 2014-2024
6.12 The Rest of the World Prostate Cancer Therapeutics Market, 2014-2024

7. Qualitative Analysis of the Prostate Cancer Therapeutics Market 2014-2024
7.1 SWOT Analysis, 2014-2024
7.2 Strengths
7.2.1 Prostate Cancer is a High Profile Disease
7.2.2 Rapidly Expanding Ageing Population
7.2.3 Targeted Therapies can Command Premium Prices
7.2.4 Strong R&D Pipeline
7.2.5 Successful Launches through Partnerships between Small/Big Pharma Companies
7.2.6 Use of Off-label Drugs is Common
7.3 Weaknesses
7.3.1 Prostate Cancer Drugs are Expensive
7.3.2 R&D Failures in Late-stage Development
7.3.3 Controversy Over the Value of New Prostate Cancer Devices
7.3.4 U.S Medical Excise Tax
7.4 Opportunities
7.4.1 Rising Incidence of cancer
7.4.2 Emerging National Markets will Drive Growth
7.4.3 Stem Cells Offer Promise
7.4.4 Advances in Diagnostic Technologies: CTC as a Biomarker
7.5 Threats
7.5.1 Concerns about Efficacy and Toxicity of Drugs
7.5.2 Who will Pay for the High Cost of Drugs and Devices?
7.5.3 Governments Decreasing Healthcare Spending
7.5.4 Increase in Generic Competition
7.5.5 Increase in the Practice of ‘Active Surveillance’
7.6 Porter’s Five Force Analysis
7.6.1 Rivalry Among Competitors [High]
7.6.2 Threat of New Entrants [High]
7.6.3 Power of Suppliers [Low]
7.6.4 Power of Buyers [High]
7.6.5 Threat of Substitutes [Low]

8. Expert Opinions
8.1 Professor Malcolm Mason, Cancer Research UK’s Prostate Cancer Expert
8.1.1 Factors Affecting the Growth of Prostate Cancer
8.1.2 Prostate Cancer: To Treat or Not to Treat?
8.1.3 Alternatives to PSA Testing
8.1.4 A Common Option for Early Stage Prostate Cancer: Radical Prostatectomy
8.1.5 Large Number of Clinical Trials Studying Prostate Cancer
8.1.6 Combination Therapy: Better Survival Rates
8.1.7 Novel Prostate Cancer Drugs: A Question of Cost
8.2 Interview with Hans Kolam, Chief Financial Officer and Helen Tuvesson, Chief Scientific Officer, Active Biotech
8.2.1 Tasquinimod: Phase III Pre-Chemotherapy Study
8.2.2 Tasquinimod: An Innovative Mode of Prostate Cancer Treatment
8.2.3 Active Biotech/Ipsen: Partnerships are Pivotal for Oncology Drug Development
8.2.4 Tasquinimod: Other Indications in the Pipeline
8.2.5 Competitive Landscape of the Prostate Cancer Drugs Market
8.2.6 The Drivers of Growth in the Prostate Market
8.3 Dr. Estuardo Aguilar-Cordova, Co-founder, CEO and Chairman, Advantagene
8.3.1 ProstAtak’s Mechanism for Prostate Cancer Prevention
8.3.2 ProsAtak’s Market Size
8.3.3 Immunotherapy: The Future for Cancer Treatment
8.3.4 Active Surveillance: A growing Trend

9. Conclusions
9.1 The Prostate Cancer Therapeutics Market, 2014-2024
9.2 The US Will Remain the Largest National Market from 2014 to 2024
9.3 Concluding Remarks

9.2 The US Will Remain the Largest National Market from 2014 to 2024
9.3 Concluding Remarks

List of Tables
Table 2.1 PSA Testing: Benefits and Limitations, 2014
Table 2.2 New Prostate Cancer Diagnostic Tests in Market, 2014
Table 3.1 The Global Prostate Cancer Therapeutics Market: Revenue ($m), Market Share (%) by Segment, 2013
Table 3.2 The Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 3.3The Global Prostate Cancer Therapeutics Market: Drivers and Restraints 2014-2024
Table 4.1 The Prostate Cancer Drugs List: Key Brands, 2014
Table 4.2 The Prostate Cancer Drugs Market: Revenue ($m), Market Share (%) by Leading
Drugs, 2013
Table 4.3 The Prostate Cancer Drugs Market Forecast, Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 4.4 Market Shares (%) of the Leading Prostate Cancer Drugs, 2013, 2018 and 2024
Table 4.5 Sanofi: Taxotere Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.6 Sanofi: Jevtana Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.7 AstraZeneca: Casodex Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.8 AbbVie: Lupron Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.9 AstraZeneca: Zoladex Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.10 Johnson & Johnson: Zytiga Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.11 Medivation/Astellas: Xtandi Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.12 Dendreon: Provenge Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.13 Bayer: Xofigo Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.14 Other Prostate Cancer Drugs: Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.15 Key Drugs in Phase III Clinical Trials, 2014
Table 4.16 Negative Phase III Clinical Trials, 2014
Table 4.17 Key Drugs in Phase II Clinical Trials, 2014
Table 4.18 Key Drugs in Phase I Clinical Trials, 2014
Table 4.19 Johnson & Johnson: Revenue ($bn) and Revenue Shares (%) by Segment, 2013
Table 4.20 Johnson & Johnson: Historical Revenue ($bn), AGR (%), CAGR (%), 2008-2013
Table 4.21 Johnson & Johnson Pharmaceuticals: Revenue ($bn), and Revenue Shares (%) by Segment, 2013
Table 4.22 Johnson & Johnson: Oncology Pharmaceuticals Segment: Revenue ($m) by Drug, 2011-2013
Table 4.23 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Company Revenue (%), 2011-2013
Table 4.24 AstraZeneca: Revenue ($bn), AGR (%), CAGR (%), 2010-2013
Table 4.25 AstraZeneca: Revenue ($bn), Revenue Shares (%) by Segment, 2013
Table 4.26 AstraZeneca: Oncology Drugs Revenue ($m), Change in Revenue (%) and Revenue Shares (%), 2012-2013
Table 4.27 AstraZeneca: Oncology Phase II and III Pipeline, 2014
Table 4.28 Sanofi: Revenue ($bn), AGR (%), CAGR (%), 2009-2013
Table 4.29 Sanofi: Sale Revenue ($bn), Revenue Shares (%) by Segment, 2013
Table 4.30 Sanofi: Oncology Sales ($m) by Product, 2012-2013
Table 4.31 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue (%), 2010-2013
Table 4.32 Sanofi: Major Compounds from Sanofi’s Oncology Pipeline, 2014
Table 4.33 AbbVie: Revenue ($bn), AGR (%), CAGR (%), 2011-2013
Table 4.34 AbbVie: Revenue ($bn) by Drug, 2011-2013
Table 5.1 The Prostate Cancer Devices Market: Revenue ($m), Market Share (%) by Segment, 2013
Table 5.2 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2014-2024
Table 5.3 Market Shares (%) of the Leading Prostate Cancer Devices Submarkets, 2013, 2018 and 2024
Table 5.4 The Brachytherapy Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2024
Table 5.5 The Radical Prostatectomy Market Forecast: Revenue ($m), AGR (%), CAGR (%),
2014-2024
Table 5.6 The External Beam Radiation Therapy Market Forecast: Revenue ($m), AGR (%),
CAGR (%), 2014-2024
Table 5.7 The HIFU Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2024
Table 5.8 The Cryotherapy Therapy Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2024
Table 5.9 Varian Medical Systems: Revenue ($bn), AGR (%), CAGR (%), 2009-2013
Table 5.10 Varian Medical Systems: Revenue ($bn), Revenue Share (%) by Segment, 2013
Table 5.11 Varian Medical Systems: Oncology Systems Revenue ($bn), Revenue Shares (%) by Segment, 2013
Table 5.12 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as
Percentage of Revenue (%), 2011-2013
Table 5.13 Elekta: Revenue ($bn), AGR (%), CAGR (%) 2009-2013
Table 5.14 Elekta: Net Sales ($bn) and Net Sales Shares (%) by Region, 2012
Table 5.15 Theragenics: Revenue ($m), AGR (%), CAGR (%) 2008-2012
Table 5.16 Theragenics: Revenue ($m), Revenue Share (%) by Business Unit, 2012
Table 6.1 The Prostate Cancer Therapeutics Market: Revenue ($m) and Market Share (%) by Region, 2013
Table 6.2 The Leading Prostate Cancer Therapeutics National Market Forecasts: Revenue ($m), AGR (%), CAGR(%), 2013-2024
Table 6.3 Market Shares (%) of the Leading Prostate Cancer Therapeutics National Markets,
2013, 2018 and 2024
Table 6.4 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%),
CAGR (%), 2013-2024
Table 6.5 The European Prostate Cancer Therapeutics Markets: Revenue ($m), Market Share (%) by Country/Region, 2013
Table 6.6 The European Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.7 The German Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.8 The French Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.9 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%),
CAGR (%), 2013-2024
Table 6.10 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.11 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table6.12 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.13 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.14 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.15 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR(%), 2013-2024
Table 6.16 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.17 The South Korean Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.18 The Mexican Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.19 The RoW Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.1 SWOT Analysis of the Prostate Cancer Therapeutics Market, 2014-2024
Table 9.1 Market Share (%) of the Leading Regional Prostate Cancer Therapeutics Markets in 2013, 2018, 2024

List of Figures
Figure 1.2 Prostate Cancer Therapeutics: Overview of Submarkets and Segments
Figure 2.1 Global Proportion (%) of Newly diagnosed Cancer by Type (Excluding Non-Melanoma Skin Cancer), 2012
Figure 2.2 Treatment Sequence for Prostate Cancer, 2014
Figure 3.1 The Global Prostate Cancer Therapeutics Market: Revenue ($m) by Segment, 2013
Figure 3.2 The Global Prostate Cancer Therapeutics Market: Market Share (%) by Segment,
2013
Figure 3.3 The Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 4.1 The Prostate Cancer Drugs Market: Revenue ($m) by Leading Drugs, 2013
Figure 4.2 The Prostate Cancer Drugs Market: Market Share (%) by Leading Drugs, 2013
Figure 4.3 The Prostate Cancer Drugs Market Forecast, Revenue ($m), AGR (%), 2013-2024
Figure 4.4 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Drug, 2018
Figure 4.5 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Drug, 2024
Figure 4.6 Sanofi: Taxotere Revenue Forecast ($m), AGR (%) 2013-2024
Figure 4.7 Sanofi: Jevtana Revenue Forecast ($m), AGR (%) 2013-2024
Figure 4.8 AstraZeneca: Casodex Revenue Forecast ($m), AGR (%),2013-2024
Figure 4.9 AbbVie: Lupron Revenue Forecast ($m), AGR (%) 2013-2024
Figure 4.10 AstraZeneca: Zoladex Revenue Forecast ($m), AGR (%) 2013-2024
Figure 4.11 Johnson & Johnson: Zytiga Revenue Forecast ($m), AGR (%),2013-2024
Figure 4.12 Medivation/Astellas: Xtandi Revenue Forecast ($m), AGR (%), 2013-2024
Figure 4.13 Dendreon: Provenge Revenue Forecast ($m), AGR (%) 2013-2024
Figure 4.14 Bayer: Xofigo Revenue Forecast ($m), AGR (%),2013-2024
Figure 4.15 Other Prostate Cancer Drugs: Revenue Forecast ($m), AGR (%), 2013-2024
Figure 4.16 Johnson & Johnson: Revenue Shares (%) by Segment, 2013
Figure 4.17 Johnson & Johnson: Historical Revenue ($bn),AGR (%), 2008-2013
Figure 4.18 Johnson & Johnson Pharmaceuticals: Revenue($bn) by Segment, 2013
Figure 4.19 Johnson & Johnson Pharmaceuticals: Revenue Shares (%) by Segment, 2013
Figure 4.20 Johnson & Johnson Oncology Pharmaceuticals Segment: Market Share (%) by Drug, 2013
Figure 4.21 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D
Expenses as Percentage of Company Revenue (%), 2011-2013
Figure 4.22 AstraZeneca: Revenue ($bn), AGR (%), 2010-2013
Figure 4.23 AstraZeneca: Revenue ($bn) by Segment, 2013
Figure 4.24 AstraZeneca: Revenue Shares (%) by Segment, 2013
Figure 4.25 AstraZeneca: Oncology Drugs Revenue Share (%) by Brand Product, 2013
Figure 4.26 AstraZeneca: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue (%), 2011-2013
Figure 4.27 Sanofi: Revenue ($bn), AGR (%), 2009-2013
Figure 4.28 Sanofi: Revenue ($bn) by Segment, 2013
Figure 4.29 Sanofi: Revenue Share (%) by Segment, 2013
Figure 4.30 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue (%), 2010-2013
Figure 4.31 AbbVie: Revenue ($bn), AGR (%),2011-2013
Figure 4.32 AbbVie: Revenue Share (%) by Drug, 2013
Figure 5.1 The Prostate Cancer Devices Market: Revenue ($m) by Segment, 2013
Figure 5.2 The Prostate Cancer Devices Market: Market Share (%) by Segment, 2013
Figure 5.3 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%), 2014-2024
Figure 5.4 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Devices
Submarkets, 2018
Figure 5.5 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Devices
Submarkets, 2024
Figure 5.6 The Brachytherapy Market Forecast: Revenue ($m), AGR (%), 2014-2024
Figure 5.7 The Radical Prostatectomy Market Forecast: Revenue ($m), AGR (%), 2014-2024
Figure 5.8 The External Beam Radiation Therapy Market Forecast: Revenue ($m), AGR (%),
2014-2024
Figure 5.9 The HIFU Market Forecast: Revenue ($m),AGR (%), 2014-2024
Figure 5.10 The Cryotherapy Therapy Market Forecast: Revenue ($m), AGR (%), 2014-2024
Figure 5.11 Varian Medical Systems: Revenue ($bn), AGR (%), 2013-2024
Figure 5.12 Varian Medical Systems: Revenue ($bn) by Segment, 2013
Figure 5.13 Varian Medical Systems: Revenue Share (%) by Segment, 2013
Figure 5.14 Varian Medical Systems: Oncology Systems Revenue ($bn) by Segment, 2013
Figure 5.15 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Segment, 2013
Figure 5.16 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Region, 2013
Figure 5.17 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as
Percentage of Revenue (%), 2011-2013
Figure 5.18 Elekta: Historical Revenue ($bn), AGR (%), 2009-2013
Figure 5.19 Elekta: Revenue Share (%) by Region, 2012
Figure 5.20 Theragenics: Revenue ($m), AGR (%), 2008-2012
Figure 5.21 Theragenics: Revenue Share (%) by Operation, 2012
Figure 5.22 Theragenics: Revenue Share (%) by Business Unit, 2012
Figure 6.1 The Prostate Cancer Therapeutics Market: Revenue ($m) by Region, 2013
Figure 6.2 The Prostate Cancer Therapeutics Market: Market Share (%) by Region, 2013
Figure 6.3 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2018
Figure 6.4 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2024
Figure 6.5 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR
(%), 2013-2024
Figure 6.6 The European Prostate Cancer Therapeutics Markets: Revenue ($m) by
Country/Region, 2013
Figure 6.7 The European Prostate Cancer Therapeutics Markets: Market Share (%) by
Country/Region, 2013
Figure 6.8 The European Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.9 The German Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.10 The French Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.11 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR
(%), 2013-2024
Figure 6.12 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.13 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR
(%), 2013-2024
Figure 6.14 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.15 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.16 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.17 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.18 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.19 The South Korean Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.20 The Mexican Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.21 The RoW Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 7.1 Porter’s Five Force Analysis of the Prostate Cancer Therapeutics Market, 2013-2023
Figure 9.1 The Prostate Cancer Therapeutics Market: Revenues ($m) by Segment in 2013, 2018, 2024
Figure 9.2 The Prostate Cancer Therapeutics Market: Market Share (%) by Region, 2024

★調査レポート[世界の前立腺がん治療市場予測:前立腺がん治療薬、前立腺がん治療デバイス] ( The Prostate Cancer Therapeutics Market 2014-2024
Opportunities for Leading Companies / VISG409047) 販売に関する免責事項
[世界の前立腺がん治療市場予測:前立腺がん治療薬、前立腺がん治療デバイス] ( The Prostate Cancer Therapeutics Market 2014-2024
Opportunities for Leading Companies / VISG409047) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆